USFDA classifies inspection of Cadila Healthcare’s Moraiya unit as OAI

07 Aug 2019

Cadila Healthcare has received a letter from the US Food and Drug Administration (USFDA) classifying the inspection conducted at the company's Moraiya facility located at Ahmedabad, Gujarat from April 22, 2019 to May 3, 2019 as 'Official Action Indicated' (OAI).

The company believes that this classification will not have any impact on the current supplies or revenues of this facility. The company is in the process of sending further updates of its corrective actions to the USFDA and remains hopeful of a positive outcome.

Cadila Healthcare operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals.

Related Cadila Healthcare Ltd. Links:

Cadila Healthcare Share Price

358.20 1.95 (0.55%) Jul 13, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 499.65
Dr. Reddys Lab 3898.60
Lupin 869.30
Piramal Enterprises 1432.20
Cadila Healthcare 358.20
View more..
Sensex vs Cadila Healthcare
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback